Search

Number of results found: 4
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page 1 of 1
Skipped to 4 results found. Page 1 of 1
    • Monday, Mar 08, 2021

    Awareness Saves Lives: Renown Goes Blue for Colorectal Cancer Awareness Month

    After a year of possibly delayed colorectal cancer screenings due to theCOVID-19 pandemic, it’s more important than ever to raise awareness for colorectal cancer. March is National Colorectal Cancer Awareness Month- a time to raise awareness for colorectal cancer and the importance of routine, life-saving screenings. Renown invites the community to join the organization in helping put an end to the preventable disease.  Blue is the designated color to bring awareness to colorectal cancer and those impacted by it. The iconic “LOVE” sculpture at the main entrance of Renown Regional Medical Center located at 1155 Mill Street in Reno, Nev. will shine brightly in blue each evening in March, serving as a visual reminder to passersby to schedule a colorectal screening. The Colorectal Cancer Alliance estimates 149,500 new cases of colon cancer will present in 2021 alone. While colorectal cancer may be the second deadliest cancer in men and women combined, it is also one of the most preventable cancers with screenings.  “Unfortunately, due to the COVID-19 pandemic, there’s been a decline in colorectal screenings nationwide,” said Tony Slonim, MD, DrPH, President and CEO of Renown Health. “We know early detection is key in preventing the spread of any cancer, and with regular screenings, we know colorectal cancer is easily detectable and treatable. As a cancer survivor, I know how important it is to get back on track with regular screenings and preventive care. Making your health a priority now will help you experience a healthier and brighter tomorrow.”   “We invite the community to join us at Renown in spreading awareness about colorectal cancer and its prevention,” said Susan Cox, director of cancer services at the Renown Institute for Cancer. “It takes all of us to put an end to colorectal cancer. If you’re up to date on your screenings, remind a loved one to schedule their next screening--as your reminder may have the power to save their life.” “Colorectal cancer usually forms from precancerous polyps, or abnormal growths, in the colon or rectum, which can become malignant without presenting any symptoms. Screening tests like stool tests, colonoscopies, and others can detect these precancerous polyps, so they can be removed by a physician before turning into cancer. Screening tests can also find colorectal cancer early, resulting in better treatment outcomes,” says Christos Galanopoulos, M.D., MBA, oncologic surgeon, VP Renown Health & Chair of Surgery for Renown Health.   Dr. Galanopoulos adds, “Most people begin screening for colorectal cancer after turning 50. However, some individuals may begin screenings earlier if they have an increased risk of colorectal cancer, such as a family history with the disease. Regardless of one’s personal or family history of colorectal cancer, it’s important to talk to your doctor about the right time to begin your screenings.”  Max J. Coppes, MD, Cancer Center Director, Renown Institute for Cancer adds, “While routine screenings are the only way to determine colorectal health, some healthy habits may reduce your risk for colorectal cancer. These factors include maintaining a healthy weight, being physically active, eating a diet rich in fresh fruits, vegetables and whole grains, limiting alcohol intake and not smoking.”  Dr. Coppes explains that, “1 in 500 Americans will test positive for Lynch Syndrome, a genetic condition that raises your risk of colon cancer, endometrial cancer, and other cancers. It is also known as hereditary nonpolyposis colorectal cancer. People with Lynch Syndrome are also susceptible to colon polyps at a younger age. The Healthy Nevada Project research team is looking at the occurrence of important inherited genetic variants in our population that increase the risk of certain diseases. These include Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome.” To enroll in The Healthy Nevada Project, a clinical study (saliva test) offering the opportunity to learn about your ancestry, diet insights and genetic risks linked to heart disease and certain cancers, including prevention strategies, at no cost, enroll here. For a limited time, Nevada residents may request a free DNA test kit that will be shipped to your home.  Renown experts encourage every adult to talk to their doctor about their colorectal cancer risk and screening options. Those looking to schedule a screening or establish care with a Renown primary care provider are invited to call us at 775-691-7308 or visit our website for more information.     About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath and Neurosciences. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®.

    Read More About Awareness Saves Lives: Renown Goes Blue for Colorectal Cancer Awareness Month

    • Cancer Care
    • Clinical Trial
    • Research and Studies

    Ovarian Cancer Survivor Shares Decision to Try Clinical Trial

    While there used to be three basic treatment options for cancer -- surgery, radiation and chemotherapy, or a combination of the three -- there's a fourth option: clinical trials. Here, a Renown patient shares her successful battle with ovarian cancer, aided by a clinical trial. Shari Flamm's battle with ovarian cancer began in 2011. She was experiencing prolonged bleeding, irregular thyroid levels and anemia and was scheduled to undergo a hysterectomy. Before the surgery, her gynecologist ran routine tests to check for cancer as a precautionary measure. All tests were negative for cancer, expect her CA 125 test. A CA 125 test measures the amount of the protein CA 125 (cancer antigen 125) in the blood. In some cases, a CA 125 test may be used to look for early signs of ovarian cancer in women with a very high risk of the disease. In most laboratories, the normal level is 0 to 35 units/ml. Flamm's CA 125 level was 121. As Flamm can attest, early diagnosis played a key role in her battle with ovarian cancer. September is Gynecologic Cancer and Ovarian Cancer Awareness Month – an important time to learn the signs, symptoms and risk factors of this type of cancer so your doctor can diagnosis the disease as early as possible. Ovarian Cancer: Round One Despite the elevated CA 125 results, her doctor recommended they move forward with the hysterectomy. But when surgery began, doctors discovered a mass. She had stage 4 cancer. The procedure was halted, the mass was biopsied and she was immediately seen by Dr. Peter Lim of the The Center of Hope. Following diagnosis, Flamm underwent surgery with Dr. Lim to remove the cancer, which had spread to part of diaphragm, spleen, colon and other organs. Three months after surgery, Flamm had recovered enough to start six rounds of chemotherapy in her hometown of Carson City. She continued working at a doctor's office during her treatment, and was grateful for Dr. Lim’s ability to co-manage her care so she could stay close to work and family. “To me, chemo was the scariest part because I didn’t like feeling sick,” Flamm says. Thankfully, her body responded well to the treatments and she was back to the things she loved. “I stated working out at the gym, even if it was only for 10 minutes,” she says. She also stayed positive by spending time with her grandchildren, attending a San Jose Sharks hockey game, going for walks and enjoying concerts. Ovarian Cancer: Round Two In November 2014, Flamm had a cancer check-up. That’s when doctors discovered three cancerous tumors. For this round, Flamm choose another treatment option -- clinical trials at Renown Institute for Cancer. Clinical trials are the studies that test whether drugs work, and inform doctors' decisions about how to treat their patients. Flamm participated in a clinical trial that featured oral-targeted therapy stronger than IV chemotherapy. The hope was for the drug to shrink her tumors, however the result was stabilization -- meaning the lumps weren’t growing or spreading. The best part of the clinical trial, Flamm says, was the constant monitoring. Between the CT scans every six weeks, a heart scan every three months and monthly doctor visits, she was confident that if the cancer started growing or spreading, her healthcare team would catch it right away. For Flamm, the benefits of the clinical trial included less hair loss, less fatigue and more time to focus on what’s important in her life -- her family. “I decided I wasn’t going to be that sick grandma on the couch with cancer,” Flamm says. After taking the oral medication for one year, Flamm developed a rash and discontinued treatment due to discomfort. Clinical Trials, Setbacks and Survival In June 2016, two of the three tumors began to grow and had to be surgically removed. Despite the setback, Flamm was determined to maintain a positive outlook. "You have to stay positive because cancer feeds off anger, depression and stress," Flamm says. Flamm was released to go home with clear margins, meaning the tumors were removed and are surrounded by a rim of normal tissue that does not have cancerous cells. Flamm says her outlook on life has changed drastically since her first cancer diagnosis. “Your whole mentality changes when cancer disturbs your life," Flann says. "The things that weren’t important, are now ever so important. I’m a lot calmer now,” Flamm says.

    Read More About Ovarian Cancer Survivor Shares Decision to Try Clinical Trial

    • Cancer Care
    • Renown Health

    Navigating Renowns Cancer Care Resources Your Essential Guide

    Cancer is challenging, but no one has to go through it alone. Patients and their loved ones can navigate the journey towards healing and recovery with the proper support and resources from Renown Health.  When faced with a cancer diagnosis, access to reliable and comprehensive cancer resources is key. These resources provide vital information, support, and guidance for patients, caregivers and loved ones throughout cancer treatment and recovery. Cancer Resources Breast Cancer Newly Diagnosed Orientation Class  Cancer Support Groups  Caregiver Support  General Cancer Support Group  Lymphedema & Physical Therapy  Men’s Prostate Cancer Support Group  Newly Diagnosed Breast Cancer Workshop  Smoking Cessation  Spiritual Center Activities & Programs  Sterling Silver 55+ Club Facebook Group  At Renown and in collaboration with community partnerships, we offer a variety of resources and specialty care programs focused on improving the quality of life after cancer including:  Cancer support groups play a crucial role in providing emotional, psychological, and practical assistance to those affected by cancer   These groups often consist of individuals who have been through similar experiences and can offer guidance, empathy, and understanding.   They provide a safe space for individuals to share their feelings, concerns, and experiences with others who truly understand what they are going through.

    Read More About Navigating Renowns Cancer Care Resources Your Essential Guide

    • HealthyNV Project
    • Research and Studies
    • Mammogram
    • Genetic
    • Cancer Care

    Optimizing Mammogram Screenings: A Genetic Approach to a Personalized Screening Schedule

    Breast cancer screening has long been a cornerstone of women's healthcare. With 1 in 8 women diagnosed with breast cancer in their lifetime1, the United States Preventive Services Task Force (USPSTF) has developed screening recommendations to help detect early-stage cancer. Notably in 2023, the USPSTF revised the recommended age for biennial mammogram screenings for women with average risk to start at age 40 instead of 502, estimated to result in 19% more lives being saved3 by starting screening earlier. While initiating screening at an earlier age offers advantages to a wide demographic, concerns about the potential of over-screening prompted research into the feasibility of identifying women with lower breast cancer risk who could safely delay mammograms. While guidelines address high-risk individuals, a notable gap exists in providing recommendations tailored to those at lower risk. To gain insight into a patient's risk level, physicians are able to utilize genetic testing to understand an individual's genetic makeup, providing precise insights into their predisposition to various health conditions, including breast cancer. Armed with this genetic information, healthcare providers could craft tailored screening strategies that align with an individual’s specific risk profile. This genetic risk-based approach underscores the value of genetics in individualizing the onset of screening to help avoid over-screening and its associated costs. Surprisingly, genetic information is not currently being widely utilized to identify women at risk of breast cancer or other diseases in clinical practice, despite its potential to make a significant positive impact for patients. A recent retrospective analysis of 25,591 women from the Healthy Nevada Project4 sheds light on the potential benefits of this genetic risk-based approach. The study classified 2,338 (9.1%) of these women as having a low genetic risk for breast cancer. What's remarkable is that these women exhibited a significantly lower and later onset of breast cancer compared to their average or high-risk counterparts. This finding suggests that it might be safe for low-risk women to delay mammogram screening by 5 to 10 years without compromising their health.

    Read More About Optimizing Mammogram Screenings: A Genetic Approach to a Personalized Screening Schedule

Number of results found: 4
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page 1 of 1
Skipped to 4 results found. Page 1 of 1